Replies to post #7206 on Galena Biopharma fka GALE

[Euripides90]

Yes this is suffering from an industry-wide attack, biotechs are easy marks because they require huge R & D.
Considering this passed $1.90 just last week and looked headed for $2.00+ where it should be based on anticipation of positive results, which were justified, "blasting" past $1.75 is hardly an exciting prospect, except for the shorts who flip for a few ticks and batter the stock with ramblings about past performance, hypothetical things that could go wrong with any bio etc. The shorts live to kill the biotechs and progress in alleviating the worst illnesses of mankind.

Pitiful performance reflected in the disappointed silence on investor Boards. All waiting for the day shorts burn.